A skin care composition for improving menopausal aging in women and use thereof

Abstract

The present application relates to a kind of skin care composition for improving female menopausal aging and its application, the skin care composition for improving female menopausal aging includes the following components: conotoxin peptide, bakuchiol, alfalfa extract and radix pseudostellariae extract, the weight ratio of conotoxin peptide, bakuchiol, alfalfa extract and radix pseudostellariae extract is (0.1-5) :(0.1-3) :(0.1-5) :(0.1-3). The four are by means of inhibiting neurotransmitter, regulating hormone etc., enhance skin health, effectively improve the problem of menopausal female skin aging, make skin firm and smooth.

Description

Technical Field

[0001] This invention relates to the field of skincare technology, specifically to a skincare composition for improving menopausal aging in women and its application. Background Technology

[0002] Menopause is a significant stage in a woman's life, typically occurring between the ages of 45 and 55. Due to declining estrogen levels, many women may experience a range of skin problems. First, the reduction in collagen and elastin causes the skin to lose elasticity. Studies show that in the first five years after menopause, type I and type III collagen can decrease by up to 30%, leading to wrinkles and sagging, especially noticeable around the eyes, mouth, and forehead, where fine lines and wrinkles become more pronounced, and facial contours lose firmness. Second, dry and dehydrated skin is very common. The decrease in estrogen levels weakens the skin's ability to retain moisture, making it rough, dull, and prone to peeling or scaling. Furthermore, many women experience increased skin sensitivity, reacting more strongly to external stimuli, leading to discomfort such as redness, itching, and stinging, and even skin problems like eczema. Skin sensitivity to light exposure may also increase, becoming more fragile and prone to sunburn. Many women around menopause report experiencing a "cliff-like" aging process, particularly affecting the face, which bears significant social responsibility, presenting substantial physical and psychological challenges.

[0003] Numerous studies have shown that hormone replacement therapy (HRT), which involves estrogen, can increase skin collagen levels and thickness. However, due to the increased risk of cancers such as breast and uterine cancer, long-term use of HRT is clearly extremely unsafe. Natural phytoestrogens, as a safe alternative, have a structure and function similar to human estrogen and can exert a bidirectional regulatory effect in the body. They can both supplement deficient estrogen and inhibit problems caused by excessive estrogen. Therefore, topical application of skincare products containing phytoestrogens is an effective measure to improve aging caused by estrogen deficiency during menopause, and it is safer and easier to adhere to than oral supplements. In addition to estrogen supplementation, targeted solutions are needed to address the most important skin concerns during menopause, such as the loss of collagen and elastin, sagging, dryness, and sensitivity, in order to comprehensively improve skin aging issues in menopausal women.

[0004] Currently, most products on the market are health supplements, and there are no skincare products specifically designed to improve the aging problems of menopausal women. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a skin care composition for improving menopausal aging in women and its application thereto. When applied to skin care products, this skin care composition can improve the problem of rapid skin aging in menopausal women.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0007] In a first aspect, the present invention provides a skin care composition for improving menopausal aging in women, comprising the following components: conotoxin peptide, psoralen, alfalfa extract and codonopsis extract, wherein the weight ratio of conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is (0.1-5):(0.1-3):(0.1-5):(0.1-3).

[0008] Preferably, the weight ratio of conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is (0.5-3):(0.1-1):(1-2):(0.5-2).

[0009] More preferably, the weight ratio of conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is (1-2):(0.5-1):(1.5-2):(0.5-1).

[0010] Preferably, the manufacturer of the conotoxin peptide is Shenzhen Weiqi Technology Co., Ltd., and the product name is conotoxin peptide.

[0011] Preferably, the manufacturer of the Codonopsis pilosula extract is Clariant Chemicals (China) Co., Ltd., and the product name is CycloRetin. TM .

[0012] Preferably, the psoralen is manufactured by Sytheon, and the product name is [model number missing]. A.

[0013] Preferably, the alfalfa extract is manufactured by Shanghai Jiakai Biotechnology Co., Ltd., and the product model is [model number missing].

[0014] The conotoxin peptide in this skincare composition effectively improves facial sagging by blocking the release of neurotransmitters from facial nerve cells, reducing excessive muscle contraction, thereby smoothing the skin surface and improving contour firmness. Bakuchiol activates estrogen receptors in the skin, enhancing skin hydration and elasticity, and slowing wrinkle formation. Alfalfa, rich in phytoestrogens, regulates hormonal balance, improves skin's water retention capacity, and keeps skin smooth and firm. Codonopsis pilosula extract enhances skin immunity, promotes blood circulation, reduces sensitivity, and repairs the skin barrier. These four ingredients work synergistically to effectively improve skin aging problems in menopausal women by inhibiting neurotransmitter release, regulating hormone levels, and enhancing skin health, resulting in firmer and smoother skin.

[0015] In a second aspect, the present invention provides the use of the skin care composition of the first aspect for improving menopausal aging in women in the preparation of skin care products.

[0016] Preferably, the skin care product is at least one of toner, lotion, cream, mask, serum or spray, and the amount of the skin care composition added is 0.5-5% of the total weight of the skin care product.

[0017] Thirdly, the present invention provides a face cream comprising the following ingredients by weight percentage: 0.5%-5% of the skin care composition described in the first aspect for improving menopausal aging in women, 0.05-0.3% of a thickener, 0.5-1% of a moisturizer, 1-10% of an emulsifier, 0.5-3% of a preservative, and 0.01-0.3% of a pH adjuster, with the balance being deionized water.

[0018] Preferably, the thickener includes at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, sclerotium gum, and cetyl alcohol.

[0019] Preferably, the moisturizer includes at least one of allantoin, sodium polyacrylate, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butanediol, glycerin, budding stalk polysaccharide, and ceramide.

[0020] Preferably, the pH adjuster includes at least one of arginine, tromethamine, and disodium EDTA.

[0021] Preferably, the emulsifier comprises at least one of the following: caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetra(ethylhexanoate), polydimethylsiloxane, stearyl alcohol, sucrose stearate, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate;

[0022] Preferably, the preservative includes at least one of 1,2-propanediol, 1,2-hexanediol, and p-hydroxyacetophenone.

[0023] Fourthly, the present invention provides a method for preparing the face cream of the third aspect, comprising the following steps:

[0024] S1. After mixing the humectant, thickener and part of deionized water evenly, homogenize the mixture at 80°C to form a homogeneous aqueous phase. Mix the emulsifier evenly at 80°C. Mix the aqueous phase and emulsifier evenly at 75-85°C to obtain a mixture.

[0025] S2. Add the preservative to the mixture obtained in step S1, stir evenly, and after the temperature drops to 35-45℃, add the components of the skin care composition and the remaining deionized water and stir evenly. Finally, add the pH adjuster to adjust the pH to obtain the face cream.

[0026] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0027] The conotoxin peptide in this skincare composition can block the release of neurotransmitters, improve facial sagging, reduce excessive muscle contraction, and enhance facial contour firmness; bakuchiol activates estrogen receptors, enhances skin moisture and elasticity, and slows down wrinkles; alfalfa regulates hormone balance, improves water retention capacity, and keeps skin smooth and firm; and codonopsis extract enhances immunity, promotes blood circulation, reduces sensitivity, and repairs the skin barrier. These four ingredients, through inhibiting neurotransmitters and regulating hormones, enhance skin health and effectively improve skin aging problems in menopausal women, leaving skin firm and smooth. Attached Figure Description

[0028] Figure 1 The keratinocyte healing status of Example 1, Comparative Example 1, and the blank group;

[0029] Figure 2 The facial improvement of the subjects in Application Example 1 and Comparative Application Example 5 is shown. Detailed Implementation

[0030] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0031] The sources of the main raw materials used in the following examples and comparative examples are as follows:

[0032] Conotoxin peptide: Manufacturer: Shenzhen Weiqi Technology Co., Ltd.; Product name: Conotoxin peptide.

[0033] Codonopsis pilosula extract: Manufacturer: Clariant Chemicals (China) Co., Ltd., Product name: CycloRetin TM ;

[0034] Bakuchiol: Manufacturer: Sytheon, Model No. A;

[0035] Alfalfa extract: Manufacturer: Shanghai Jiakai Biotechnology Co., Ltd., Model:

[0036] Unless otherwise specified, all other materials, reagents, etc. used in the examples and comparative examples are commercially available.

[0037] Example 1

[0038] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 1.5:0.6:1.6:0.8, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0039] Example 2

[0040] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 0.1:0.1:5:3, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0041] Example 3

[0042] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 5:3:0.1:0.1, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0043] Example 4

[0044] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 0.5:0.1:1:0.5, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0045] Example 5

[0046] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 3:1:2:2, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0047] Example 6

[0048] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 1:0.5:1.5:0.5, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0049] Example 7

[0050] A skincare composition for improving menopausal aging in women includes conotoxin peptide, psoralen, alfalfa extract and codonopsis extract in a weight ratio of 2:1:2:1, wherein the total weight of the conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is 50 parts.

[0051] Comparative Example 1

[0052] The difference between Comparative Example 1 and Example 1 is that the total weight of the skin care composition remains unchanged, no cone snail toxin peptide is added, and the missing amount is made up by using psoralen, alfalfa extract and codonopsis extract in a weight ratio of 0.6:1.6:0.8.

[0053] Comparative Example 2

[0054] The difference between Comparative Example 2 and Example 1 is that the total weight of the skin care composition remains unchanged, no bakuchiol is added, and the missing amount is made up by using cone snail toxin peptide, alfalfa extract and codonopsis extract in a weight ratio of 1.5:1.6:0.8.

[0055] Comparative Example 3

[0056] The difference between Comparative Example 3 and Example 1 is that the total weight of the skin care composition remains unchanged, alfalfa extract is not added, and conotoxin peptide, psoralen and codonopsis extract in a weight ratio of 1.5:0.6:0.8 are used to make up for the missing amount.

[0057] Comparative Example 4

[0058] The difference between Comparative Example 4 and Example 1 is that the total weight of the skin care composition remains unchanged, no Codonopsis pilosula extract is added, and the missing amount is made up by using conotoxin peptide, psoralen and alfalfa extract in a weight ratio of 1.5:0.6:1.6.

[0059] Test Example 1

[0060] The raw material components of the skin care compositions in Examples 1-7 and Comparative Examples 1-4 were mixed according to the formulated amounts, and DMSO of equal mass was added and mixed thoroughly to obtain a skin care composition test sample. This skin care composition test sample is for in vitro testing only.

[0061] 1. Assay for the expression rate of estrogen receptor 2 (ESR2) in cells

[0062] Activation of facial estrogen receptors plays a crucial role in mitigating menopausal aging. Estrogen helps improve skin elasticity and firmness by promoting collagen production and enhancing skin hydration, reducing wrinkles and dryness, and improving skin tone and texture. Furthermore, estrogen regulates sebum secretion, reducing acne and oiliness, and enhances antioxidant capacity to combat free radical damage. Therefore, appropriately activating estrogen receptors on the skin can help improve the aging state of skin during menopause.

[0063] The skincare composition test sample of Example 1 and the skincare composition test samples of Comparative Examples 1-4 were tested according to the following steps, and the results are shown in Table 1.

[0064] Human keratinocytes (HaCaT) were revived (Guangzhou Genio Biotechnology Co., Ltd.). The test conditions were: incubator temperature 37±1℃, humidity 90±5%, carbon dioxide 5±1%. Cells were cultured and treated according to groups, followed by testing, specifically estrogen receptor 2 (ESR2) expression. The test method is as follows:

[0065] (1) The cell suspension was seeded into a 96-well cell culture plate at a density of 2000 cells / well. 100 μL of DMEM high glucose culture medium (Gibco) containing 10% fetal bovine serum was added to each well and cultured for 24 h.

[0066] (2) Sample feeding: 100 μL of culture medium was added to the blank control group, and 100 μL of culture medium containing 0.05% skin care composition test sample was added to the sample group, and the samples were cultured for 24 h.

[0067] (3) Detection of estrogen receptor 2 (ESR2) gene expression: The expression level of estrogen receptor 2 (ESR2) gene in HaCaT cells of each group was detected by real-time quantitative PCR. The RNA reverse transcription kit (Applied Biosystems) was used for RT reactions, and ESR2 was detected using specific primers and probe Hs01584024_m1 provided by Applied Biosystems. Standard 2 was used. -ΔΔCt Calculate the relative gene expression levels at the mRNA level.

[0068] The estrogen-promoting effect of the sample was expressed as the increase rate of ESR2 receptors, calculated using the following formula:

[0069] Estrogen receptor increase rate (%) = (ESR2 expression level) 样品组 / ESR2 expression level 空白对照组 -1)*100%

[0070] Table 1. ESR2 increase rate data for each group of skincare compositions.

[0071] Group / Performance ESR2 increase rate / % Example 1 23.91 Comparative Example 1 0.73 Comparative Example 2 2.41 Comparative Example 3 0.10 Comparative Example 4 1.32

[0072] 2. Cell scratch healing test

[0073] The scratch assay is an effective way to evaluate the skin barrier repair capacity. By observing cell migration and regeneration after a scratch, it provides a direct indication of the cells' ability to repair a damaged barrier. In this experiment, comparing cell healing speeds allows for the assessment of the impact of different treatments on skin repair.

[0074] The skincare composition test samples of Examples 1-7 and Comparative Examples 1-4 were tested according to the following steps, and the results are shown in Table 2.

[0075] Human keratinocytes (HaCaT) resuscitation (Guangzhou Genio Biotechnology Co., Ltd.) were tested under the following conditions: incubator temperature 37±1℃, humidity 90±5%, carbon dioxide 5±1%. Cells were cultured and treated according to groupings, followed by testing. Specifically, the test utilized two-well cell healing slides, and the testing method is as follows:

[0076] (1) Seed the cell suspension into a 2-well cell healing plate at a density of 6 × 10⁶ cells / well. 5 Add 100 μL of DMEM high glucose medium (Gibco) containing 10% fetal bovine serum to each well and incubate for 24 h.

[0077] (2) Drug administration: 100 μL of culture medium was added to the blank control group, and 100 μL of culture medium containing 0.05% skin care composition test sample was added to the sample group. The insert was removed and cultured for another 24 h.

[0078] (3) Photographs: The cell scratches of each group were photographed under a microscope at 0h and 24h, and the area of ​​the scratches was measured.

[0079] The skin barrier repair capability of the sample is represented by the cell scratch healing rate, which is calculated as follows:

[0080] Cell healing rate (%) = (cell scratch area) 0h -Cell scratch area 24h ) / cell scratch area oh

[0081] Table 2. Cell scratch healing rate data for each group of skincare compositions.

[0082] Group / Performance Cell scratch healing rate / % Example 1 56.23 Example 2 23.94 Example 3 27.41 Example 4 35.03 Example 5 37.25 Example 6 42.61 Example 7 47.32 Comparative Example 1 12.31 Comparative Example 2 10.42 Comparative Example 3 9.42 Comparative Example 4 9.03 Blank control group 7.32

[0083] 3. Collagen and elastin expression test

[0084] The dermis of the skin is 75% composed of collagen. Fibrous collagen and elastin form a network structure that provides skin tension and gives tissue elasticity. Together, they form the basic substances of the skin, maintaining the structural integrity of the dermis and making the skin supple and firm. Type I collagen is the most abundant protein in the skin. The distribution of type I collagen in zebrafish is the same as that in humans and shows a high degree of conservation. The elastin gene is also highly conserved. By testing the expression of the zebrafish type I collagen gene (col1a1a) and the corresponding elastin gene (Eln1), it is possible to assess whether the sample has the effect of promoting collagen and elastin regeneration, reshaping the dermal structure, and achieving anti-wrinkle and firming effects on the skin.

[0085] Therefore, this efficacy example evaluates the efficacy of the compositions prepared in Examples 1-7 and Comparative Examples 1-4 by detecting zebrafish collagen and elastin genes. The experiments were conducted according to the conditions in Table 3, and the results are shown in Table 3. The specific steps include:

[0086] (1) Sample preparation: The test samples of the compositions prepared in Examples 1-7 and Comparative Examples 1-4 were homogenized with water at a mass ratio of 0.5% at high speed, then sonicated for 10 min. Fish embryo culture medium was then added to prepare the required concentration. After shaking for 30 s, the mixture was centrifuged at 6500 r / min for 10 min, and the supernatant was used for testing. The concentration of the test solution must ensure a mortality rate of <10% for zebrafish embryos (embryos without heartbeat characteristics are defined as dead). Three concentration groups were set up for testing.

[0087] (2) Test steps:

[0088] 1) Select healthy zebrafish embryos that are 6 days old post-fertilization. The test requires a blank control group (fish embryo culture medium) and a sample group (test samples). Each well contains 6 zebrafish and 2.5 mL of fish embryo culture medium. Incubate at 28±1℃ for 24±1 h post-fertilization. Collect the 6 zebrafish from each well into a 1.5 mL tube, remove the culture medium, add 0.5 mL of RNAlater solution, and freeze.

[0089] 2) Remove the RNA later solution and wash three times with PBS. Place on ice, remove the PBS, and add 500 μL of TRIzol reagent. Homogenize the embryos using a pellet mill and place on ice for 10 min. Add 100 μL of chloroform, vortex for 1 min, and place on ice for 5 min. Centrifuge the sample for 20 min, transfer the supernatant to a 1.5 mL centrifuge tube, add 250 μL of isopropanol, vortex for 1 min, place on ice for 10 min, and centrifuge for 20 min. Remove all supernatant, add 500 μL of ethanol, vortex for 1 min, centrifuge for 5 min, and place on ice for 10 min. Repeat this step three times. Remove the ethanol, centrifuge the sample for 5 min, and air dry the sample in a fume hood with the lid off for 10 min. Add 10 μL of DNase / RNase-free ultrapure distilled water and heat at 55°C for 15 min. Dilute the RNA sample to 1000 ng / 7 μL with DNase / RNase-free ultrapure distilled water. RNA was synthesized into cDNA using a PrimerScript RT kit (Takara; Cat no. RR047A) containing gDNA Eraser, and stored frozen. Primer mixtures and real-time PCR master mixtures were prepared for each primer. The cDNA samples were diluted 10-fold with DNase / RNase-free ultrapure distilled water. For each well of a 96-well plate, 9 μL of the PCR master mixture and 1 μL of diluted cDNA sample were added. The 96-well PCR plates were sealed with optical adhesive film, centrifuged for 5 minutes, and then subjected to real-time PCR amplification. The gene sequences are as follows: β-actin: 5'-GCTGAC AGGATGCAGAAGGA-3' and 5'-TAGAAGCATTTGCGGTGGAC-3', type I collagen gene (col1a1a): 5'-TAGCCCCTATGGACGTTGGT-3' and 5'-CGCAGGTCTAAG CAAGTGGA-3', and elastin gene (Eln1): 5'-AAAACCAGGTTACGGCTCTGT-3' and 5'-TCCTCCTGGATAAGCTCCGTATC-3'. β-actin was used as an internal reference gene to calculate the relative expression level of the target gene.

[0090] The effect of the composition on promoting collagen and elastin production in the skin is expressed as the gene promotion rate, calculated as follows:

[0091] Promotion rate (%) = (Gene expression level in test group - Gene expression level in blank group) / Gene expression level in blank group × 100%

[0092] Table 3. Data on the promotion rates of collagen and elastin by each group of skincare compositions.

[0093] Group / Performance Collagen promotion rate / % Elastin promotion rate / % Example 1 73.23 128.04 Example 2 37.95 72.41 Example 3 45.29 89.47 Example 4 47.93 94.76 Example 5 52.94 97.32 Example 6 61.83 101.84 Example 7 63.05 102.94 Comparative Example 1 24.95 32.30 Comparative Example 2 21.36 31.94 Comparative Example 3 17.43 27.84 Comparative Example 4 15.21 23.94

[0094] As shown in Tables 1-3, Examples 1-7 and Comparative Examples 1-4, the four components of the skincare composition significantly affect its effects on promoting estrogen, repairing the skin barrier, replenishing collagen, and improving skin laxity. The anti-aging effect is better when conotoxin peptide, psoralen, alfalfa extract, and codonopsis extract are used in combination. The anti-aging performance decreases when any one of these four components is missing. This may be because conotoxin peptide, psoralen, alfalfa extract, and codonopsis extract have a synergistic effect, appropriately upregulating the expression of estrogen receptor 2 (ESR2) in keratinocytes; promoting cell migration in keratinocytes; and promoting skin wound healing. In addition, the composition can also promote the expression of collagen I and III and elastin in dermal fibroblasts. Therefore, while supplementing estrogen, the composition can also specifically supplement collagen and elastin, effectively improving its anti-aging effect and alleviating aging problems in menopausal women.

[0095] Based on the data from Examples 1-7, it can be seen that when the weight ratio of conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is (0.5-3):(0.1-1):(1-2):(0.5-2), the estrogen supplementation and anti-aging effects of the skin care composition can reach a better level. More preferably, the weight ratio of conotoxin peptide, psoralen, alfalfa extract and codonopsis extract is (1-2):(0.5-1):(1.5-2):(0.5-1).

[0096] Application Example 1 and Comparative Application Examples 1-4

[0097] The skincare compositions of Example 1 and Comparative Examples 1-4 were added to face creams at a concentration of 5 wt% to obtain face creams of Application Example 1 and Comparative Application Examples 1-4. The formulations are shown in Table 4.

[0098] The preparation methods of the face creams in Application Example 1 and Comparative Application Examples 1-4 include the following steps:

[0099] The preparation method of face cream includes the following steps:

[0100] S1. After mixing the humectant, thickener and part of deionized water evenly, homogenize them at 80°C to form a uniform aqueous phase. Mix the emulsifier evenly at 80°C. Mix the aqueous phase and emulsifier evenly at 80°C to obtain a mixture.

[0101] S2. Add the preservative to the mixture obtained in step S1, stir evenly, and after the temperature drops to 40°C, add the components of the skin care composition and the remaining deionized water and stir evenly. Finally, add the pH adjuster to adjust the pH to obtain the face cream.

[0102] Table 4. Cream formulations for Application Example 1 and Comparative Application Examples 1-4

[0103]

[0104] Comparative Application Example 5

[0105] In contrast, the face cream in Application Example 5 does not contain any skincare composition, but uses an equal amount of deionized water instead of the skincare composition, and the preparation method is the same as in Application Example 1.

[0106] Test Example 2

[0107] This test case verifies the effect of the face creams used in Application Example 1 and Comparative Application Examples 1-5 on improving facial aging and barrier damage in menopausal female subjects. The experimental data are shown in Table 5.

[0108] Forty-eight female participants aged 45-65 in menopause were selected according to the "Cosmetic Safety Technical Specifications" (2015) using a self-assessment questionnaire. Participants were randomly divided into six groups of eight. Volunteers applied the sample (Application Example 1 and Control Examples 1-5) to their entire face twice daily, morning and evening. Data was collected on day 0 and day 28. After each visit, volunteers washed their faces with facial cleanser and sat quietly for 30 minutes in an air-conditioned room with a temperature of 21±1℃ and humidity of 50±10%. Before and after application, subjects used VISIA-CR to photograph and analyze under-eye wrinkles, calculating the improvement rate. Before and after application, subjects used the TewaMeter skin moisture loss test probe to measure the transepidermal water loss (TEWL) value of the cheekbone, calculating the facial TEWL improvement rate. Before and after application, subjects used a skin stratum corneum moisture measurement probe. The CM825 measures skin hydration and calculates the improvement rate of facial hydration. Subjects used a skin elasticity testing probe before and after use. The MPA580 measures skin firmness F4 and calculates the firmness F4 improvement rate. The calculation method for each value's improvement rate is as follows: Improvement rate = |(T0)| 测量值 -T28 测量值 )| / T0 测量值 *100%. Data is shown in Table 5.

[0109] In this test case, the improvement rate of firmness F4, the improvement rate of under-eye wrinkle area, the improvement rate of facial hydration, and the improvement rate of facial TEWL were used to represent the improvement of the face cream prepared by the composition on the subject's facial sagging, wrinkles, dryness, and barrier damage.

[0110] Table 5. Human trial data for each group of face cream samples.

[0111]

[0112]

[0113] Experimental conclusions: From Table 5, Figure 1-2 It is evident that the face cream prepared using the skincare composition of Example 1 for improving menopausal aging in women has a significantly better anti-aging effect compared to the face creams prepared using the skincare compositions of Comparative Examples 1-4, which contain only three active ingredients. This is consistent with the results of Test Example 1. This also demonstrates that the four components of this invention—conotoxin peptide, bakuchiol, alfalfa extract, and codonopsis extract—have a synergistic effect. Face creams containing this composition can target the most important issues of menopausal skin—loss of collagen and elastin, sagging, dryness, and sensitivity—achieving anti-aging, anti-wrinkle, moisturizing, and barrier repair effects, thereby comprehensively improving skin aging problems in menopausal women.

[0114] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A skincare composition for improving aging during menopause in women, characterized in that, It is composed of the following components: conotoxin peptide, psoralen, alfalfa extract, and codonopsis extract, wherein the weight ratio of conotoxin peptide, psoralen, alfalfa extract, and codonopsis extract is (1-2):(0.5-1):(1.5-2):(0.5-1); wherein the manufacturer of conotoxin peptide is Shenzhen Weiqi Technology Co., Ltd., and the product name is Conotoxin Peptide; the manufacturer of codonopsis extract is Clariant Chemicals (China) Co., Ltd., and the product name is CycloRetin. TM The psoralen mentioned is manufactured by Sytheon, and its product name is Sytenol. ® A; The alfalfa extract mentioned: manufactured by Shanghai Jiakai Biotechnology Co., Ltd., product name: Mulan Yin ® .

2. The use of the skincare composition of claim 1 for improving menopausal aging in women in the preparation of skincare products.

3. The application of the skincare composition for improving menopausal aging in women as described in claim 2 in the preparation of skincare products, characterized in that, The skin care product is at least one of toner, lotion, cream, mask, serum or spray, and the amount of the skin care composition added is 0.5-5% of the total weight of the skin care product.

4. A face cream, characterized in that, The raw materials include the following weight percentages: 0.5%-5% of the skin care composition for improving menopausal aging in women as described in claim 1, 0.05-0.3% thickener, 0.5-1% moisturizer, 1-10% emulsifier, 0.5-3% preservative and 0.01-0.3% pH adjuster, with the balance being deionized water.

5. The face cream as described in claim 4, characterized in that, The raw material is selected from at least one of (a)-(e): (a) The thickener comprises at least one of xanthan gum, carbomer, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, sclerotium gum, and cetyl alcohol; (b) The moisturizer comprises at least one of allantoin, sodium polyacrylate, hydrogenated lecithin, betaine, β-glucan, trehalose, caprylyl glycol, dipropylene glycol, sodium hyaluronate, 1,2-butanediol, glycerin, budding stalk polysaccharide, and ceramide; (c) The pH adjuster includes at least one of arginine, tromethamine, and disodium EDTA; (d) The emulsifier comprises at least one of the following: caprylic / capric triglyceride, C14-22 alcohol, C12-20 alkyl glucoside, cetearyl glucoside, isononyl isononanoate, pentaerythritol tetra(ethylhexanoate), polydimethylsiloxane, stearyl alcohol, sucrose stearate, hydroxystearic acid, polymethylsilsesquioxane, pentaerythritol distearate, and sucrose stearate; (e) The preservative includes at least one of 1,2-propanediol, 1,2-hexanediol, and p-hydroxyacetophenone.

6. The method for preparing the face cream according to claim 4 or 5, characterized in that, Includes the following steps: S1. After mixing the humectant, thickener and part of deionized water evenly, homogenize them at 80°C to form a uniform aqueous phase. Mix the emulsifier evenly at 80°C. Mix the aqueous phase and emulsifier evenly at 75-85°C to obtain a mixture. S2. Add the preservative to the mixture obtained in step S1, stir evenly, and after the temperature drops to 35-45℃, add the components of the skin care composition and the remaining deionized water and stir evenly. Finally, add the pH adjuster to adjust the pH to obtain the face cream.

Images